Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226277 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01226277 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 42 participants.
The verdict
NCT01226277, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.
Interventions
- DRUG GDC-0917
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226277
The ClinicalTrials.gov registry entry for NCT01226277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0917 is the first listed.
NCT01226277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01226277 about?
NCT01226277 is a clinical study titled "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma". This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.
What is the current status of trial NCT01226277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2010-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01226277?
The interventions under investigation include: GDC-0917 (DRUG).
Who is sponsoring clinical trial NCT01226277?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.